HLA Matching at the Eplet Level Protects Against Chronic Lung Allograft Dysfunction

Area of Science:

• Transplantation immunology
• Genetics and genomics
• Clinical medicine

Background:

• Lung transplantation (LTx) outcomes are often limited by chronic lung allograft dysfunction (CLAD).
• Traditional donor selection criteria (urgency, ABO, size) do not routinely include human leukocyte antigen (HLA) matching.
• Development of anti-HLA antibodies post-LTx is linked to poorer graft survival and CLAD.

Purpose of the Study:

• To investigate whether donor-recipient HLA incompatibility, analyzed by eplet mismatches, predicts CLAD after LTx.
• To determine the specific HLA loci and eplet mismatches most associated with CLAD development.
• To differentiate the impact of HLA eplet mismatches on specific CLAD phenotypes like bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS).

Main Methods:

• Retrospective analysis of 175 LTx cases performed between 2008-2012.
• HLA typing using sequence-based typing and Luminex sequence-specific oligonucleotide.
• Eplet mismatch analysis using HLAMatchmaker software to correlate with CLAD incidence.

Main Results:

• HLA-DRB1/3/4/5+DQA/B eplet mismatch was a significant predictor of overall CLAD (HR 3.77, p < 0.001).
• This specific eplet mismatch strongly predicted restrictive allograft syndrome (RAS) (HR 8.3, p < 0.001) but not bronchiolitis obliterans syndrome (BOS) (HR 1.92, p = 0.237).
• HLA-A/B eplet mismatches did not independently predict CLAD but offered additional prognostic stratification.

Conclusions:

• Epitope-level HLA matching is crucial for defining immune compatibility in LTx.
• HLA-DRB1/3/4/5+DQA/B eplet mismatches are key drivers of CLAD, especially RAS.
• Incorporating eplet mismatch analysis into donor selection could improve long-term lung allograft survival.